IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v17y2020i24p9514-d464585.html
   My bibliography  Save this article

Real World Use of Antidiabetic Drugs in the Years 2011–2017: A Population-Based Study from Southern Italy

Author

Listed:
  • Ylenia Ingrasciotta

    (Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98125 Messina, Italy)

  • Maria Paola Bertuccio

    (Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98125 Messina, Italy)

  • Salvatore Crisafulli

    (Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98125 Messina, Italy)

  • Valentina Ientile

    (Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98125 Messina, Italy)

  • Marco Muscianisi

    (Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy)

  • Luca L’Abbate

    (Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98125 Messina, Italy)

  • Maurizio Pastorello

    (Palermo Local Health Unit, Department of Pharmacy, 90127 Palermo, Italy)

  • Vincenzo Provenzano

    (Regional Referral Centre for Insulin Pump Implantation and Diabetes, Civic Hospital, Partinico, 90047 Palermo, Italy)

  • Alessandro Scorsone

    (Regional Referral Centre for Insulin Pump Implantation and Diabetes, Civic Hospital, Partinico, 90047 Palermo, Italy)

  • Salvatore Scondotto

    (Department of Epidemiologic Observatory, Health Department of Sicily, 90127 Palermo, Italy)

  • Gianluca Trifirò

    (Department of Diagnostic and Public Health, University of Verona, 37134 Verona, Italy)

Abstract

Diabetes mellitus is a metabolic disease characterized by chronic hyperglycemia. The availability of new antidiabetic drugs (ADs) has led to complex treatment patterns and to changes in the patterns of specific drug utilization. The aim of this population-based study was to describe the pattern of antidiabetic drugs (ADs) use in Southern Italy in the years 2011–2017, in relation to the updated type 2 diabetes mellitus (T2DM) therapy guidelines. A retrospective cohort study was conducted on T2DM patients using data from the Palermo Local Health Unit (LHU) claims database and diabetologist registry. The first-line treatment was investigated and incident treatments were identified and characterized at baseline in terms of demographics, complications, comorbidities, concomitant drugs and clinical parameters. Persistence to AD treatment was also evaluated. During the study period, one-third of first ever ADs users started the treatment with ADs other than metformin, in contrast to guideline recommendations. Among 151,711 incident AD treatments, the male to female ratio was 1.0 and the median age was 66 (57–75) years. More than half (55.0%) of incident treatments discontinued the therapy during the first year of treatment. In Italy, general practitioners (GPs) can only prescribe first-generation ADs, while the prescription of more recently marketed ADs, such as GLP-1RA, DPP4i and SGLT2i, is restricted to diabetologists only, based on a therapeutic plan. The role of GPs in the management of T2DM in Italy should be re-evaluated.

Suggested Citation

  • Ylenia Ingrasciotta & Maria Paola Bertuccio & Salvatore Crisafulli & Valentina Ientile & Marco Muscianisi & Luca L’Abbate & Maurizio Pastorello & Vincenzo Provenzano & Alessandro Scorsone & Salvatore , 2020. "Real World Use of Antidiabetic Drugs in the Years 2011–2017: A Population-Based Study from Southern Italy," IJERPH, MDPI, vol. 17(24), pages 1-21, December.
    • Handle: RePEc:gam:jijerp:v:17:y:2020:i:24:p:9514-:d:464585
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/17/24/9514/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/17/24/9514/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Heidi Storgaard & Lise L Gluud & Cathy Bennett & Magnus F Grøndahl & Mikkel B Christensen & Filip K Knop & Tina Vilsbøll, 2016. "Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis," PLOS ONE, Public Library of Science, vol. 11(11), pages 1-23, November.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Anastasios Tentolouris & Panayotis Vlachakis & Evangelia Tzeravini & Ioanna Eleftheriadou & Nikolaos Tentolouris, 2019. "SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects," IJERPH, MDPI, vol. 16(16), pages 1-27, August.

    More about this item

    Keywords

    ;
    ;
    ;
    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:17:y:2020:i:24:p:9514-:d:464585. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.